tiprankstipranks
Hansa Biopharma AB (MX:HNSAN)
:HNSAN
Mexico Market
HNSAN
Hansa Biopharma AB
RESEARCH TOOLSreports

Hansa Biopharma AB (HNSAN) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HNSAN Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Hansa
Biopharma AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HNSAN Stock 12 Month Forecast

Average Price Target

―
Based on 1 Wall Street analysts offering 12 month price targets for Hansa Biopharma AB in the last 3 months. The average price target is $187.64 with a high forecast of $187.64 and a low forecast of $187.64. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$187.64Average Price Target$187.64Lowest Price Target$187.64
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:HNSAN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$187.64
Buy
―
Reiterated
07/24/26
Douglas Tsao Reiterates Buy on Hansa, Maintains $103 Price Target Amid Strategic Pivot and Operational Recovery
Wedbush Analyst forecast on MX:HNSAN
David Nierengarten
Wedbush
Wedbush
$125.7
Buy
―
Initiated
01/07/26
Hansa Biopharma initiated with an Outperform at WedbushHansa Biopharma initiated with an Outperform at Wedbush
Leerink Partners Analyst forecast on MX:HNSAN
Thomas Smith
Leerink Partners
Leerink Partners
$185.81
Buy
―
Initiated
11/26/25
Hansa Biopharma's Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:HNSAN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$187.64
Buy
―
Reiterated
07/24/26
Douglas Tsao Reiterates Buy on Hansa, Maintains $103 Price Target Amid Strategic Pivot and Operational Recovery
Wedbush Analyst forecast on MX:HNSAN
David Nierengarten
Wedbush
Wedbush
$125.7
Buy
―
Initiated
01/07/26
Hansa Biopharma initiated with an Outperform at WedbushHansa Biopharma initiated with an Outperform at Wedbush
Leerink Partners Analyst forecast on MX:HNSAN
Thomas Smith
Leerink Partners
Leerink Partners
$185.81
Buy
―
Initiated
11/26/25
Hansa Biopharma's Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline
Stocks with the Highest Top Analyst Consensus in the General Sector
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
CBRSCerebras Systems, Inc. Class A
FRVOFervo Energy Company Class A
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hansa Biopharma AB

3 Months
Douglas TsaoH.C. Wainwright
Success Rate
10/25 ratings generated profit
40%
Average Return
+2.53%
Copying Douglas Tsao's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.53% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
11/25 ratings generated profit
44%
Average Return
+3.05%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 44.00% of your transactions generating a profit, with an average return of +3.05% per trade.
2 Years
Douglas TsaoH.C. Wainwright
Success Rate
14/25 ratings generated profit
56%
Average Return
+6.51%
Copying Douglas Tsao's trades and holding each position for 2 Years would result in 56.00% of your transactions generating a profit, with an average return of +6.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HNSAN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
4
4
4
4
2
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
4
4
4
2
In the current month, HNSAN has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HNSAN average Analyst price target in the past 3 months is 187.64.
Each month's total comprises the sum of three months' worth of ratings.

HNSAN Financial Forecast

HNSAN Earnings Forecast

Next quarter’s earnings estimate for HNSAN is $10.34 with a range of -$2.76 to $29.44. The previous quarter’s EPS was -$4.60. HNSAN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.30% of the time in the same period. In the last calendar year HNSAN has Performed in-line its overall industry.
Next quarter’s earnings estimate for HNSAN is $10.34 with a range of -$2.76 to $29.44. The previous quarter’s EPS was -$4.60. HNSAN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.30% of the time in the same period. In the last calendar year HNSAN has Performed in-line its overall industry.

HNSAN Sales Forecast

Next quarter’s sales forecast for HNSAN is $528.82M with a range of $0.00 to $1.98B. The previous quarter’s sales results were $86.35M. HNSAN beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 59.14% of the time in the same period. In the last calendar year HNSAN has Outperformed its overall industry.
Next quarter’s sales forecast for HNSAN is $528.82M with a range of $0.00 to $1.98B. The previous quarter’s sales results were $86.35M. HNSAN beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 59.14% of the time in the same period. In the last calendar year HNSAN has Outperformed its overall industry.

HNSAN Stock Forecast FAQ

What is MX:HNSAN’s average 12-month price target, according to analysts?
Based on analyst ratings, Hansa Biopharma AB’s 12-month average price target is 187.64.
    What is MX:HNSAN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:HNSAN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Hansa Biopharma AB a Buy, Sell or Hold?
        Hansa Biopharma AB has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Hansa Biopharma AB’s share price target?
          The average share price target for Hansa Biopharma AB is 187.64. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $187.64 ,and the lowest forecast is $187.64. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Hansa Biopharma AB?
            Hansa Biopharma AB’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
              How can I buy shares of Hansa Biopharma AB?
              To buy shares of MX:HNSAN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.